Objectives: For most laboratories, methotrexate (MTX) concentrations are routinely monitored by fluorescence polarization immunoassay (FPIA). In anticipation of an announced withdrawal of the FPIA reagent on the Abbott TD x FL x (Abbott Diagnostics, Abbott Park, IL), we have evaluated a new reagent kit developed by Abbott on the Architect i1000, based on chemiluminescent microparticle immunoassay (CMIA).
. 2, 3 HDMTX remains a mainstay in the treatment of acute lymphoblastic leukemia, osteosarcoma, and non-Hodgkin lymphoma. MTX is poorly metabolized, and most of the dose is excreted unchanged in urine. 7-Hydroxy-methotrexate (7-OH-MTX) is the main extracellular metabolite of MTX. 4 Common side effects include bone marrow depression and mucositis, but acute nephrotoxicity induced by the precipitation of MTX and 7-OH-MTX in renal tubules is very serious. However, toxicity incidence can be alleviated through diverse measures. HDMTX-induced nephrotoxicity is prevented through substantial hydration and alkalinization of urine to enhance elimination. Folinic acid rescue, to restore intracellular folate concentration, is guided by plasma creatinine and MTX therapeutic drug monitoring (TDM). 5, 6 Nevertheless, renal impairment causes delayed MTX elimination and ineffective folinic acid rescue. As a last resort, hydrolysis of MTX by carboxypeptidase can be used. One administration can inactivate more than 95% of MTX by degradation into 2,4-diamino-N10-methylpteroic acid (DAMPA) and glutamic acid Figure 1 . 6 Thus, MTX plasma concentration monitoring is crucial for the detection of a poor MTX elimination as quickly as possible. Until recently, plasma MTX concentrations were routinely monitored by fluorescence polarization immunoassay (FPIA) after HDMTX administration. FPIA was the widespread method for HDMTX TDM, but it was gradually substituted by various assays because of its progressive marketing cessation. In recent years, different immunoassays have been marketed for routine hospital assays. ARK Diagnostics provides an immunoassay for Roche Diagnostics, Abbott Diagnostics (Abbott Park, IL), Siemens, and Beckman systems; Ortho Clinical Diagnostics provides an immunoassay (EMIT) using a Syva Siemens system. [7] [8] [9] [10] More recently, Abbott Diagnostics has provided an MTX assay kit for the Architect i1000 system. The purpose of this study was to evaluate the characteristics of this new chemiluminescent microparticle immunoassay (CMIA) immunoassay by comparison with both the Abbott TD x FL x analyzer and a liquid chromatographytandemmass spectrometry method (LC-MS/MS).
Materials and Methods

Patients
All plasma patient samples (n ¼ 75) tested in this work were derived from an ongoing drug monitoring program and were reported in accordance with ethical guidelines. Characteristics of patients (n ¼ 27) are summarized in Table 1 . Informed consent was not required, but all samples were deidentified and anonymized. Only K 3 EDTA plasma samples were used in this study.
Chemicals, Reagents, and Standard Solutions
All solvents and reagents were of high-performance liquid chromatography (HPLC) grade and purchased from VWR International (Fontenay-sous-Bois, France). MTX solution (25 mg/mL, NaCl 0.9%) was purchased from Mylan (Saint Priest, France), DAMPA was purchased from Schircks laboratories (Jona, Switzerland), and 7-OH-MTX and 13 C 2 H 3 -MTX, used as the internal standard, were purchased from Alsachim (Illkirch, France). Abbott Diagnostics provides two different MTX assay kits, one for FPIA used on the Abbott TD x FL x and one for CMIA used with the Architect i1000 system. For these two immunoassays, plasma multilevel calibrators and quality controls (QCs) were provided by Abbott Diagnostics. In-house prepared QCs and plasma multilevel calibrators containing MTX were used for LC-MS/MS assays. 
FPIA
The assay was performed according to the manufacturer's instructions (Abbott Diagnostics). Calibrators, controls, or patient plasma samples (100 mL) were transferred into reaction cells and submitted to the Abbott TD x FL x instrument for automated analysis. The analytical measurement range was 0.03 to 1.00 mmol/L, and samples containing MTX at higher concentrations were diluted with reagent provided by Abbott Diagnostics. The lower limit of quantitation was 0.03 mmol/L.
CMIA
The assay was performed according to the manufacturer's instructions (Abbott Diagnostics). Calibrators, controls, or patient plasma samples (100 mL) were transferred into reaction cells and submitted to an Architect i1000 system for automated analysis. The analytical measurement range was 0.04 to 1.50 mmol/L, and samples containing MTX at higher concentrations were diluted with free drug plasma reagent provided by Abbott Diagnostics. The lower limit of quantitation (LLOQ) was 0.04 mmol/L.
LC-MS/MS Assay
The method used was previously published. 11 Briefly, 50 mL of plasma calibrator, QC, or patient sample was precipitated by 100 mL methanol/0. The method was linear up to 50 mmol/L, and intraday and interday QC coefficients of variation (CVs) were below 8.3%. The lower limit of quantitation was 0.025 mmol/L, and samples containing MTX at higher concentrations were diluted with free drug plasma. The standard line slope CV percentage was less than 3%, and the slope difference was less than 6%. The method was validated in human plasma over the concentration range of 0.05 to 50 lmol/L for MTX.
Validation Procedures
Inaccuracy and Imprecision
Inaccuracy and imprecision were evaluated by analyzing QC samples at low, medium, and high concentrations. 12, 13 For intraday validation, 15 samples of each low and high control were analyzed on the same day. For interday validation, concentrations of the QC samples were determined on 30 separate days. Inaccuracy was defined as the percentage of deviation from the nominal level and imprecision as the percent CV within a single run (intra-assay) and between different days (interassay). The performance were judged acceptable when observed error was less than allowable error and not acceptable when the observed error was greater than allowed error. The allowable errors used were the company claims for CMIA (<10%) or FPIA (<10%) methods and 15% for the LC-MS/MS method.
12,13
Carryover Effects Carryover effects were assessed by testing successively three high levels QCs (H1, H2, and H3) and three low levels QCs (L1, L2, and L3). This step was reproduced five times. If no statistical difference between L1 and L3 averages using a Student test was found, the procedure was judged free of carryover effects.
Cross-Reactivity and Interference Assessment
The antibody cross-reactivity between MTX metabolites and related products was determined. MTX-free plasma was spiked with three levels of DAMPA (0.03 mmol/L, 1.5 mmol/L, and 3 mmol/L) or 7-OH-MTX (1 mmol/L, 5 mmol/L, and 25 mmol/L).
Potential of interference with hemolytic, lipemic, and icteric plasma samples was evaluated by spiking MTX-free hemolytic, lipemic, or icteric plasma samples to a final MTX concentration of 1 mmol/L. Three different hemolytic, lipemic, or icteric plasma samples were studied.
Limit of Detection, Limit of Quantification, Linearity, and Stability These data were provided by Abbott Diagnostics laboratory. Samples must be analyzed within 3 hours after loading on the Architect system. The method was linear from 0.04 to 1.5 mmol/L. The lower limit of quantification was 0.04 mmol/L. The stability of plasma samples stored at -20 C for at least 3 months, at þ4 C for 7 days, or at room temperature for 3 days was checked. The mean concentration at each level should be within 615% of the nominal concentration.
(GraphPad Software, La Jolla, CA). The Passing-Bablok test was used for the method comparison and performed with MedCalc software 14.12 (MedCalc Software, Ostend, Belgium).
Method Comparison
We have compared the CMIA method with two validated methods used in the laboratory. The first comparison concerned the widespread FPIA method on the Abbott TD x FL x system. The second one was done with the LC-MS/MS method. The same 75 plasma samples were analyzed with the three methods. The range of MTX plasma concentration samples, monitored by LC-MS/MS, was 0.029 to 62 mmol/L.
Results
Inaccuracy and Imprecision
The inaccuracy and imprecision, determined for both intraruns and interruns, are summarized in Table 2 . Intraday and interday QC CVs were below 3.68% for the CMIA method. For MTX, the intraday inaccuracy was between -6.37% and þ3.52%, while interday performance was between -3.70% and 7.90%.
Carryover Effects, Cross-Reactivity Assessment, Interference, and Stability Carryover effects proved to be moderate and acceptable, and any statistical difference between L1 and L3 could not be established using a Student test. The means 6 SEMs of L1 and L3 were 0.0732 6 0.0007348 mmol/L and 0.0722 6 0.0008602 mmol/L, respectively. Table 3 indicates antibody cross-reactivity obtained with three concentrations of DAMPA and 7-OH-MTX. Whatever the concentration tested, 7-OH-MTX did not crossreact with the antibody used in the CMIA kit, while DAMPA systematically cross-reacted with the antibody even for concentrations less than 0.05 mmol/L. In-house evaluation of potential interference posed by icteric, lipemic, and hemolyzed samples showed stable values Table 4 .
Stability was guaranteed in plasma at -20 C for 3 months and in plasma stored at þ4 C for 7 days or at room temperature for 3 days.
Comparison to FPIA and LC-MS/MS Methods
A good correlation was found between CMIA and FPIA with a correlation coefficient of r ¼ 0.9969 (95% confidence interval [CI], 0.995-0.998), as well as between CMIA and LC-MS/MS with a correlation coefficient of r ¼ 0.9985 (95% CI, 0.997-0.999). The Passing-Bablok method comparison test showed no significant difference between the two methods with no significant deviation from linearity Figure 2A and Figure 2C . Figure 2B and Figure 2D show the Bland-Altman systematic difference for the two method comparisons.
To complete the method comparison, we have monitored the ability of the new method to lead to identical clinical decisions as reference methods. The threshold of 0.15 mmol/L or less was used to decide whether the patient would stay hospitalized. Regarding this cutoff, we determined agreement, the concordance coefficient (named the j coefficient), and, more specifically, sensitivity and specificity, which are useful to compare a new method with a reference method. Whatever the reference method considered (FPIA or LC-MS/MS), CMIA allowed us to obtain very similar results, with percentage of agreement up to 97% and a j coefficient up to 94%. The CMIA method had similar sensitivity and specificity with the threshold used. Results are reported in Table 5 .
Discussion
We describe the performance of a new automated assay based on the CMIA principle developed on the Abbott Architect i1000 system to determine MTX plasma concentrations. The main objective of this work was to complete an evaluation of this new reagent to ensure, as simply as possible, the continuity of MTX plasma concentration monitoring when the Abbott TD x FL x system is definitively stopped. Intraday and interday imprecision did not exceed 4% for all concentrations tested (Table 2) . Method accuracy was within -6.37% and þ4.57% for intrarun and interrun. This method achieved an LLOQ of 0.04 mmol/L, and the signal in the blank matrix remained inferior to the LLOQ (data not shown). These performances are consistent with TDM and pharmacokinetic studies of MTX.
The second purpose was to evaluate the performance at MTX concentrations less than 0.1 mmol/L. This was an important matter because, according to the established protocols, plasma concentrations less than 0.1 to 0.15 mmol/L determine an effective elimination of MTX dose and allow the discharge of the patients from the hospital. Two recently published articles reported problems with two reagent kits. In 2012, a team published a contrivance to "drop" the LLOQ of MTX with the EMIT reagent kits used on the Siemens Viva-E instrument. 8 In 2014, a French study reported an overestimation of the plasma concentration of MTX with the EMIT Siemens reagent kit. 10 With the CMIA reagent kit, whatever the reference method considered (FPIA or LC-MS/MS), CMIA obtains very similar results, with percentage of agreement up to 97% and a j coefficient up to 94%. The CMIA method presents similar sensitivity and specificity with the threshold used. Unfortunately, because of antibody crossreactivity between DAMPA and MTX, neither the Abbott CMIA reagent nor the Abbott FPIA kit for the Abbott TD x FL x or ARK Diagnostics reagent can be used to monitor MTX concentrations up to 48 to 72 hours after carboxypeptidase administration (Table 3 ). [14] [15] [16] After 48 hours, because the DAMPA half-life ranges from 5 to 9 hours, the immunoassay can be used again. In this context, the only way to determine MTX plasma concentrations is to use a chromatographic separation, like our LC-MS/MS method.
11,14
Conclusion
These results comparing CMIA and FPIA or LC-MS/ MS methods are consistent and indicate that therapeutic drug monitoring of MTX with the CMIA reagent kit on the Abbott Architect i1000 system is a suitable and welcome alternative to the FPIA method on the Abbott TD x FL x . Nevertheless, cross-reactivity with DAMPA remains a limitation, whatever the immunoassay used. 
